Paris and Boston, October 21st, 2020. Ariana® Pharma a leading digital health company today announced the appointment of Kia Motesharei, PhD to its board of directors. Dr. Motesharei joins existing directors Mohammad Afshar, MD, PHD President and CEO, Felix Frueh, PhD, Isabelle Buckle, PhD, Adam Afshar and Daniel Bernier.
Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
“His significant insights will be invaluable to us as we develop novel partnerships around our Explainable AI Driven Precision Medicine platform across multiple therapeutic areas” said Mohammad Afshar. “On behalf of Ariana and the Board of Directors, I welcome Kia and look forward to drawing upon his strategic, operational and business development judgment.”
Dr. Motesharei is currently Senior Vice President of Business Development & Corporate Strategy with Akcea Therapeutics. Most recently, Kia was Vice President, Global Head Licensing & Business Development, Neurology & Immunology at Merck KGaA. Prior to that, Kia was Vice President of Business Development & Alliance Management at Dyax, Chief Business Officer at the French biotech company Genfit, and Vice President of Corporate Development at ActivX.
Kia has a successful track record of over 100 transactions which include research and strategic alliances, product and technology licensing, distribution, divestitures, and M&A agreements with major pharmaceutical and biotechnology companies in the US, Europe, Japan, China, LATAM, and the Middle East. In addition, he has been involved in a number of financing activities.
Kia received his BA in Chemistry from Colorado College and his PhD in Organic Chemistry from the University of California, Los Angeles. He completed his postdoctoral training at The Scripps Research Institute as an NIH Fellow.
“I am thrilled and look forward to joining the dedicated professionals at Ariana as the company expands the application of its AI technology platform to optimize clinical trial outcomes to enable its partners deliver their therapeutics products to patients more effectively and with higher probability of success and lower risk ” said Dr. Motesharei.
About Ariana Pharma
Ariana Pharma is a leading digital health Company focused on developing advanced therapeutic decision support systems. Using its KEM® Explainable Artificial Intelligence (XAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and identify the best clinical endpoints, the best responders and the best potential synergistic drugs. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as FACS), microbiota, Patient Reported Outcomes as well as Real World Evidence data. Combining advanced data analytics with regulatory expertise, Ariana helps translate findings into innovative clinical plans. With a growing number of successful therapeutic development applications, KEM® is the only FDA-reviewed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology treatment selection system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012. Further information is available at www.arianapharma.com.